Previous 10 | Next 10 |
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 23, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-select...
Manuscript Provides Comprehensive Summary of Positive Results from Clinical and Preclinical TD-1473 Studies Conducted to Date Gut-Selective Pan-JAK Inhibition with TD-1473 Has Demonstrated Minimal Systemic Drug Exposure, Local Target Engagement and Trends Toward Reduced Markers of Ulcer...
The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE: BHVN ) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who ne...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 9, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selecti...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q4 2019 Earnings Call Feb 24, 2020 , 5:00 p.m. ET Operator Continue reading
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Theravance Biopharma, Inc. (TBPH) Q4 2019 Earnings Conference Call February 24, 2020 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Philip Worboys - Senior Vice President, Research and Translational ...
Theravance Biopharma (NASDAQ: TBPH ): Q4 GAAP EPS of -$1.17 misses by $0.06 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- YUPELRI® (revefenacin) is realizing strong customer acceptance and market uptake, in partnership with Mylan - Phase 1 of TD-5202 single-ascending dose and multiple-ascending dose studies evaluated the safety and tolerability of TD-5202 in healthy subjects; data showed TD-5202 was...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...